WaveMan
WaveMan · Company
RXRX · Recursion Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RXRX Recursion Pharmaceuticals (RXRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001601830
Quote by TradingView
Form 144 · 15
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
181
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $55.5K priced

What the filings say about RXRX

Insiders, 180 days
-$1.5M net sold
5 sellers · 29% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.2M
15 notices

Recursion Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, RECURSION PHARMACEUTICALS, INC. insiders sold a net $1.5M of stock across 435 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
HERSHBERG ROBERT
Director
SELL
2026-10-07 SECtraded 2026-10-06
25,000
$125.0K
-3.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 15.4% of the 162,156 shares held after it.
  • 2 other insiders sold within 30 days.
  • 181 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HERSHBERG ROBERT sold about $125.0K of RXRX under a 10b5-1 plan on Oct 6, 2026; 2 other insiders sold within 30 days and 181 funds added in the latest 13F quarter.
Borgeson Blake
Director
SELL
2026-10-07 SECtraded 2026-10-06
50,000
$242.0K
-3.8%
Context
  • 72 earlier Form 4 trades (code P or S) here by this insider (72 sales), the last on Sep 1, 2026.
  • The trade is 0.8% of the 6,108,287 shares held after it.
  • 2 other insiders sold within 30 days.
  • 181 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Borgeson Blake sold about $242.0K of RXRX under a 10b5-1 plan on Oct 6, 2026; 2 other insiders sold within 30 days and 181 funds added in the latest 13F quarter.
Khan Najat
CEO and President
SELL
2026-09-10 SECtraded 2026-09-08
22,408
$78.8K
+18.7%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 5, 2026.
  • The trade is 1.1% of the 2,072,890 shares held after it.
  • 2 other insiders sold within 30 days.
  • 181 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Khan Najat sold about $78.8K of RXRX under a 10b5-1 plan on Sep 8, 2026; 2 other insiders sold within 30 days and 181 funds added in the latest 13F quarter.
Borgeson Blake
Director
SELL
2026-09-02 SECtraded 2026-09-01
30,000
$100.2K
+10.5%
Context
  • 71 earlier Form 4 trades (code P or S) here by this insider (71 sales), the last on Aug 4, 2026.
  • The trade is 0.5% of the 6,158,287 shares held after it.
  • 1 other insider sold within 30 days.
  • 181 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Borgeson Blake sold about $100.2K of RXRX under a 10b5-1 plan on Sep 1, 2026; 1 other insider sold within 30 days and 181 funds added in the latest 13F quarter.
Borgeson Blake
Director
SELL
2026-08-06 SECtraded 2026-08-04
30,000
$97.5K
+18.0%
Context
  • 70 earlier Form 4 trades (code P or S) here by this insider (70 sales), the last on Jul 7, 2026.
  • The trade is 0.5% of the 6,188,287 shares held after it.
  • No other insider sold within 30 days.
  • 181 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Borgeson Blake sold about $97.5K of RXRX on Aug 4, 2026; 181 funds added in the latest 13F quarter.
435 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 430 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.5M over 180 days
-$643.5K over 90 days
below 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
181 funds bought in last quarter
more than 87% of Pharma & Biotech
Revenue
+26.9% year over year
more than 70% of Pharma & Biotech
Margin
-863.4% net margin
below 84% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
31.1% of the float short (float per yahoo 2026-10-27) · 4.4 days to cover · settled 2026-10-15
more than 99% of Pharma & Biotech
What changed in the last 30 days
Oct 7Director Borgeson Blake sold $242.0K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 7Director HERSHBERG ROBERT sold $125.0K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Director Borgeson Blake filed to sell $242.0K by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 6Director HERSHBERG ROBERT filed to sell $125.0K by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch RXRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-33.7%12M
-50%-30%-10%+10%2025-102025-122026-022026-042026-062026-082026-10 2025-12-02 · Borgeson Blake sold $961.4K2026-01-06 · Borgeson Blake sold $959.2K2026-02-03 · Borgeson Blake sold $924.0K2026-03-03 · Borgeson Blake sold $588.2K2025-10-23 · Gibson Christopher sold $570.0K2025-12-22 · Khan Najat sold $548.6K2026-10-06 · Borgeson Blake sold $242.0K2025-11-04 · Gibson Christopher sold $208.4K2025-12-04 · Gibson Christopher sold $185.2K2025-12-19 · Gibson Christopher sold $180.0K2026-01-20 · Gibson Christopher sold $178.8K2026-01-05 · Gibson Christopher sold $170.0K2025-11-19 · Gibson Christopher sold $166.4K2026-02-04 · Gibson Christopher sold $164.8K2026-07-07 · Borgeson Blake sold $158.5K2026-06-05 · Gibson Christopher sold $144.8K2026-04-22 · Gibson Christopher sold $144.4K2026-02-19 · Gibson Christopher sold $138.4K2026-05-07 · Gibson Christopher sold $134.8K2026-03-23 · Gibson Christopher sold $130.0K2026-10-06 · HERSHBERG ROBERT sold $125.0K2026-04-07 · Gibson Christopher sold $124.0K2026-05-22 · Gibson Christopher sold $123.2K2026-06-02 · Borgeson Blake sold $110.4K2026-05-05 · Borgeson Blake sold $105.6K2026-09-01 · Borgeson Blake sold $100.2K2026-08-04 · Borgeson Blake sold $97.5K2026-03-09 · Khan Najat sold $94.8K2026-04-07 · Borgeson Blake sold $93.0K2025-12-29 · Taylor Ben R sold $89.4K2026-06-05 · Khan Najat sold $84.4K2026-09-08 · Khan Najat sold $78.8K2026-02-18 · Taylor Ben R sold $41.4K2026-03-17 · Taylor Ben R sold $27.0K2026-06-03 · Bumpus Namandje sold $15.5K2026-06-18 · Bumpus Namandje sold $12.6K2026-10-06 · Borgeson Blake filed to sell $242.0K2026-10-06 · HERSHBERG ROBERT filed to sell $125.0K2026-09-08 · Najat Khan filed to sell $78.8K2026-09-01 · Borgeson Blake filed to sell $100.2K2026-08-21 · Gibson Christopher filed to sell $262.0K2026-08-20 · Gibson Christopher filed to sell $255.0K2026-08-19 · Gibson Christopher filed to sell $327.5K2026-08-18 · Gibson Christopher filed to sell $80.4K2026-08-13 · Gibson Christopher filed to sell $331.0K2026-08-12 · Gibson Christopher filed to sell $168.5K2026-08-10 · Gibson Christopher filed to sell $326.8K2026-08-07 · Gibson Christopher filed to sell $325.4K2026-08-04 · Borgeson Blake filed to sell $97.5K2026-08-04 · Gibson Christopher filed to sell $244.9K2026-07-30 · Gibson Christopher filed to sell $225.0K2026-07-29 · Gibson Christopher filed to sell $151.4K2026-07-27 · Gibson Christopher filed to sell $152.7K2026-07-21 · Gibson Christopher filed to sell $304.3K2026-07-20 · Gibson Christopher filed to sell $289.8K2026-07-17 · Gibson Christopher filed to sell $296.7K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RXRX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
50,304,691 sh
$184.6M
ARK Investment Management LLC
41,337,632 sh
$151.7M
STATE STREET CORP
34,706,130 sh
$127.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
31,131,599 sh
$114.3M
BAILLIE GIFFORD & CO
23,487,907 sh
$86.2M

Congress trades in RXRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RXRX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Borgeson Blake
Filed 2026-10-06
$242.0K
HERSHBERG ROBERT
Filed 2026-10-06
$125.0K
Najat Khan
Filed 2026-09-08
$78.8K
Borgeson Blake
Filed 2026-09-01
$100.2K
Gibson Christopher
Filed 2026-08-21
$262.0K

RXRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$40.9M position · as of 2026-07-31
2.6%
Global X HealthTech ETF
$439.7K position · as of 2026-05-31
1.8%
First Trust Nasdaq Artificial Intelligence and Robotics ETF
$11.2M position · as of 2026-06-30
1.5%
American Beacon ARK Transformational Innovation Fund
$2.0M position · as of 2026-06-30
1.2%
ARK Innovation ETF
$60.8M position · as of 2026-07-31
1.1%
Themes Generative Artificial Intelligence ETF
$256.1K position · as of 2026-06-30
0.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
0 active
4
Multi-phase
3 active
What changed recently
REC-7735 in Participants With Solid Tumors
2026-09-18 · Not Yet Recruiting → Recruiting
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · 1.
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$9.6M
$3.5M
$3.3M
-87%
+23%
2024
$8.5M
$1.9M
$6.0M
-78%
-8%
2023
$8.6M
$10.7M
$4.1M
-68%
-7%
2022
$6.3M
-$5.8M
$2.0M
-75%
-11%
2021
$673.6K
$21.8M
$647.8K
-45%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.5M sold by insiders over 180 days, 181 funds added last quarter, $3.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RXRX financials

Revenue growth
+26.9%
XBRL, annual
Net margin
-863.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$54.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-945.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$352.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.01x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-73.74x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-56.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-41.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-48.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.5B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-17.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$74.7M$58.8M$44.6M$39.8M
Operating income-$648.1M-$479.0M-$350.1M-$245.7M
Net income-$644.8M-$463.7M-$328.1M-$239.5M
EPS (diluted)-1.44-1.69-1.58-1.36
Operating cash flow-$371.8M-$359.2M-$287.8M-$83.5M
Cash$743.3M$594.4M$391.6M$549.9M
Long-term debt$9.6M$19.0M$1.1Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

RXRX Stock Sonar score 6/7 axes

Find similar shapesCompare

RXRX ranks highest on institutional and government (87th percentile) and growth (70th), and lowest on insider conviction (18th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
51
Inputs
  • Return on equity-56.6% · 50 pct, sector of 545
  • Return on assets-41.3% · 52 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-48.8% · 52 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.01x · 79 pct, sector of 352
  • Cash flow to debt-73.74x · 9 pct, sector of 371
Growth
70
Inputs
  • Revenue growth, YoY+26.9% · 70 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
18
Inputs
  • Net Form 4 buying (codes P and S), 180d-$987K · 35 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
87
Inputs
  • Funds adding, latest quarter181 · 87 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
42
Inputs
  • Short interest, % of float+31.1% · 4 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+5.7% · 80 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RXRX filings, in plain words

Are Recursion Pharmaceuticals insiders buying or selling RXRX?

In the 180 days to 2026-10-28, Recursion Pharmaceuticals insiders were net sellers, a net $1.5M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of RXRX?

Yes. 15 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $3.2M of stock; the latest, by Borgeson Blake, was filed 2026-10-06.

Read the full summary

In the 180 days to 2026-10-28, Recursion Pharmaceuticals insiders were net sellers of RXRX, a net $1.5M across purchases and sales reported on Form 4 by 5 sellers. 29% of the 14 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 15 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $3.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies